Although patients with RAS pathway lesions could be considered for targeted therapy, such as MEK inhibitors, the other lesions are not currently amenable to targeted therapy, and the sheer genetic diversity seen in T-ALL IF will make identification of effective agents challenging. The gene discussed is MAP2K7; the disease is acute lymphoblastic leukemia.